Past performance
About Aarti Pharmalabs Ltd Aarti Pharmachem Limited, established in 2019, specializes in the production of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine Derivatives in India. The company has strategically expanded its manufacturing capabilities, initially commissioning its first API unit in Dombivali in 2001 and subsequently launching additional units in Tarapur and Vapi to serve regulated markets. Notably, in 2023, Aarti Pharmachem enhanced its Xanthine production capacity to 5,000 tonnes per annum, indicating robust growth and scaling of operations.
Following a demerger from Aarti Industries Limited, Aarti Pharmachem became a separate entity under Aarti Pharmalabs Limited, effective from October 17, 2022, with operations retroactive to July 1, 2021. This strategic separation involved transferring all assets and liabilities of the Pharma Business Undertaking to Aarti Pharmachem. The company also went public with the listing of over 90 million equity shares in January 2023, reflecting its ongoing commitment to growth and market presence.
Performance overview